Chanuka Wijewardhana

Chanuka Wijewardhana

Auto-generated profile, based on publicly available information

Chanuka Wijewardhana

Department of Microbiology and Immunology, University of Western Ontario, London, ON, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YGYong Gao
Yong Gao
CWChanuka Wijewardhana
Chanuka Wijewardhana
JMJamie Mann
Jamie Mann
It is acknowledged that vaccines remain the best hope for eliminating the HIV-1 epidemic. However, the failure to produce effective vaccine immunogens and the inability of conventional delivery strategies to elicit the desired immune responses remains a central theme and has ultimately led to a significant roadblock in HIV vaccine development. Consequently, significant efforts have been applied to generate novel vaccine antigens and delivery agents, which mimic viral structures for optimal immune induction. Here we review the latest developments that have occurred in the nanoparticle vaccine field, with special emphasis on strategies that are being utilized to attain highly immunogenic, systemic and mucosal anti-HIV humoral and cellular immune responses. This includes the design of novel immunogens, the central role of antigen-presenting cells, delivery routes and biodistribution of nanoparticles to lymph nodes. In particular, we will focus on virus-like-particle (VLP) formulations and their preclinical uses within the HIV prophylactic vaccine setting.